Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q16868421> ?p ?o }
Showing triples 1 to 35 of
35
with 100 triples per page.
- Q16868421 subject Q8616356.
- Q16868421 subject Q8878163.
- Q16868421 abstract "Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR is an oncogenic driver and patients with somatic mutations, particularly an exon 19 deletion or exon 21 L858R mutation, within the tyrosine kinase domain have activating mutations that lead to unchecked cell proliferation. Overexpression of EGFR causes inappropriate activation of the anti-apoptotic Ras signaling pathway, found in many different types of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, preventing completion of the signal transduction cascade.".
- Q16868421 bioavailability "52.0".
- Q16868421 casNumber "1204313-51-8".
- Q16868421 drugbank "DB00530".
- Q16868421 fdaUniiCode "9G6U5L461Q".
- Q16868421 pubchem "22024915".
- Q16868421 thumbnail Icotinib.svg?width=300.
- Q16868421 wikiPageWikiLink Q10926084.
- Q16868421 wikiPageWikiLink Q14864419.
- Q16868421 wikiPageWikiLink Q14865565.
- Q16868421 wikiPageWikiLink Q14890102.
- Q16868421 wikiPageWikiLink Q16951366.
- Q16868421 wikiPageWikiLink Q206077.
- Q16868421 wikiPageWikiLink Q226995.
- Q16868421 wikiPageWikiLink Q3658562.
- Q16868421 wikiPageWikiLink Q40924.
- Q16868421 wikiPageWikiLink Q496.
- Q16868421 wikiPageWikiLink Q8616356.
- Q16868421 wikiPageWikiLink Q8878163.
- Q16868421 wikiPageWikiLink Q9368.
- Q16868421 bioavailability "52.0".
- Q16868421 casNumber "1204313".
- Q16868421 drugbank "DB00530".
- Q16868421 pubchem "22024915".
- Q16868421 unii "9".
- Q16868421 type ChemicalSubstance.
- Q16868421 type Drug.
- Q16868421 type ChemicalObject.
- Q16868421 type Thing.
- Q16868421 type Q8386.
- Q16868421 comment "Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR is an oncogenic driver and patients with somatic mutations, particularly an exon 19 deletion or exon 21 L858R mutation, within the tyrosine kinase domain have activating mutations that lead to unchecked cell proliferation.".
- Q16868421 label "Icotinib".
- Q16868421 depiction Icotinib.svg.